Abstract:Alzheimer’s disease (AD), the most common form of dementia, causes memory loss, cognitive decline, and behavioural changes, affecting over 32 million people globally. Current AD treatments that focus on single-target intervention often fail to significantly slow disease progression and may not be effective for all patients. Given AD’s complex nature, a more effective approach may involve targeting multiple pathways simultaneously. This study proposes the use of a cycle-consistent adversarial network to design multi-target directed ligands (MTDL-GAN), drugs designed to inhibit two primary AD target enzymes simultaneously. Our targets of interest are acetylcholinesterase (AChE), beta-secretase 1 (BACE1), and glycogen synthase kinase 3 beta (GSK3), which are known to have significant impacts on the progression and development of AD, each with a different mechanism of action. Inhibitor libraries were curated from ChEMBL27 and characterized to represent each inhibitor domain, resulting in 69 AChE, 572 BACE1, and 246 GSK3 inhibitors. The MTDL-GAN was trained on these unpaired datasets to generate molecules with dual-target properties. Domain similarity metrics and molecular docking simulations were employed to validate the generated molecules’ structural and binding properties. The proposed method successfully transformed molecules from the original inhibitor domains to the target MTDL domain while preserving structural similarity to the original datasets. The generated molecules demonstrated promising in silico dual-binding affinity, with favourable physicochemical properties and synthetic tractability. Notably, several molecules surpassed the binding scores of investigational drugs in phase 2/3 clinical trials. These hit MTDL molecules are publicly available for medicinal chemists’ research.

Multi-target-directed-ligands acting as enzyme inhibitors and receptor ligands

Advancement of Multi-Target Drug Discoveries and Promising Applications in the Field of Alzheimer's Disease.

Rational Design of Multi-Target-Directed Ligands: Strategies and Emerging Paradigms.

Multi-Target-Directed Ligands as an Effective Strategy for the Treatment of Alzheimer's Disease.

Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors

Development of multiple-target anti-Alzheimer′s agents

Recent Advances In The Rational Drug Design Based On Multi-Target Ligands

Recent Advances in the Rational Drug Design Based on Multi-target Ligands.

Systematic Investigation of Dual-Target-Directed Ligands

Recent advances in multitarget-directed ligands via in silico drug discovery

What are the challenges with multi-targeted drug design for complex diseases?

Molecular Hybridization as a Tool in the Design of Multi-target Directed Drug Candidates for Neurodegenerative Diseases

Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist

Rationally Designed Multitarget Anti-HIV Agents

Multitarget-Directed Ligands Hitting Serotonin Receptors: A Medicinal Chemistry Survey

Design of multivalent ligand targeting G-protein-coupled receptors.

MTDL-GAN: De novo Design of Multi-Target Directed Ligands for Alzheimer’s Disease from Unpaired Sets of Target-Focused Chemical Library

[Multi-Target Therapeutics and New Drug Discovery].

Multiple Target Drug Design Using LigBuilder 3

Innovative pathological network‐based multitarget approaches for Alzheimer's disease treatment

Recent Molecular Targets and Their Ligands for the Treatment of Alzheimer Disease